PLIANT THERAPEUTICS INC
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
On January 3, 2025, Johannes "Hans" Hull, our Chief Business Officer, adopted a trading plan, or the Hull 10b5-1 Sales Plan, intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. Under the Hull 10b5-1 Sales Plan, which goes into effect on May 4, 2025, an aggregate of 104,327 shares of the Company’s common stock (the “Hull Authorized Shares”) may be sold. The Hull 10b5-1 Sales Plan, which was entered into during an open trading window under the
Company’s insider trading policy, will be in effect until the earlier of (1)May 31, 2026, or (2) the date on which all Hull Authorized Shares have been sold under the Hull 10b5-1 Sales Plan.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.